Is the Biden Administration Ultimately Good for Gold - and Gold Royalties?

With spending financed by deficits, increased public debt, and global uncertainty, it's no wonder many gold analysts expect prices to break all-time highs in '24. It also has investors turning to a unique "Gold Royalty" strategy offering the potential of rising gold prices without the operational risks of mining or physical gold storage.

See why this gold royalty alternative has so much

Robert J. Polzer net worth and biography

Robert Polzer Biography and Net Worth

EVP of Zoetis

Robert J. Polzer, Ph.D., is Executive Vice President and President, Research and Development at Zoetis, the world’s leading animal health company and a member of the Fortune 500. In this role, he is responsible for leading a global organization that discovers, develops and registers new products, including genetic testing, vaccines, diagnostics and therapeutics that help predict, prevent, detect and treat animal health conditions in the eight core species that Zoetis serves. He also leads teams that develop new sensor and biodevice instruments to complement the core portfolio.

Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics where he led research and development activities to discover and register innovative solutions. He has been pivotal in advancing the company’s recent innovations, including monoclonal antibody platforms across species and therapeutic areas and a growing portfolio of companion animal parasiticides. He has also fostered external innovation collaborations with Colorado State University, which is involved in identifying new companion animal allergy and dermatology solutions and developing new immunotherapies that could pave the way for alternatives to antibiotics in food-producing animals, as well as with Regeneron to explore the connections between animal and human health.

What is Robert J. Polzer's net worth?: The estimated net worth of Robert J. Polzer is at least $445,799.38 as of August 9th, 2023. Dr. Polzer owns 2,353 shares of Zoetis stock worth more than $445,799 as of December 11th. This net worth evaluation does not reflect any other assets that Dr. Polzer may own. Learn More about Robert J. Polzer's net worth.
How old is Robert J. Polzer?: Dr. Polzer is currently 54 years old. There are 7 older executives and no younger executives at Zoetis. The oldest executive at Zoetis is Ms. Roxanne Lagano, Executive VP and Chief Human Resources Officer & Global Operations, who is 58 years old. Learn More on Robert J. Polzer's age.
How do I contact Robert J. Polzer?: The corporate mailing address for Dr. Polzer and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Robert J. Polzer's contact information.
Has Robert J. Polzer been buying or selling shares of Zoetis?: Robert J. Polzer has not been actively trading shares of Zoetis during the last quarter. Most recently, Robert J. Polzer sold 1,179 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a transaction totalling $223,939.26. Following the completion of the sale, the executive vice president now directly owns 2,353 shares of the company's stock, valued at $446,928.82. Learn More on Robert J. Polzer's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, insiders at the sold shares 9 times. They sold a total of 45,114 shares worth more than $8,077,347.12. The most recent insider tranaction occured on November, 21st when CEO Kristin C Peck sold 13,000 shares worth more than $2,298,920.00. Insiders at Zoetis own 0.1% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 11/21/2023.

Robert J. Polzer Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/9/2023	Sell	1,179	$189.94	$223,939.26	2,353

Robert J. Polzer Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $189.46

$184.68

$190.15

50 Day Range

MA: $171.83

$151.46

$184.62

2 Week Range

Now: $189.46

$140.76

$194.99

Volume

3,199,155 shs

Average Volume

1,950,183 shs

Market Capitalization

$86.98 billion

P/E Ratio

38.51

Dividend Yield

0.81%

Beta

0.85

Is the Biden Administration Ultimately Good for Gold - and Gold Royalties?

From Edge On The Street | Ad